{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:46:46Z","timestamp":1754146006922,"version":"3.41.2"},"reference-count":0,"publisher":"Consortium of Multiple Sclerosis Centers","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMSC"],"abstract":"<jats:p>Background: A wearing-off effect has been reported in people with multiple sclerosis (MS) receiving ocrelizumab and other monoclonal antibodies. We sought to describe the real-world occurrence of wearing-off effect among people with MS in Canada treated with ocrelizumab.\nMethods: Canadian self-reports coded to the Medical Dictionary for Regulatory Activities preferred term therapeutic response shortened (which included reports using the terms wearing-off, crap gap, wore off, or end-of-cycle phenomenon) between November 5, 2008, and March 15, 2023, were identified from the Roche Global Safety Database. Cases were then linked to patient-level data from the Canadian Roche Patient Support Program (COMPASS). Only people with MS who had received 3 or more doses of ocrelizumab were included.\nResults: A total of 10,055 people with MS in Canada received 3 or more doses of ocrelizumab within COMPASS. Therapeutic response shortened was reported 140 times among 138 unique cases (1.3%) over an average of 7.4 infusions. Discontinuation of ocrelizumab was generally uncommon. In the overall COMPASS population, 11.4% (1143 of 10,055) discontinued ocrelizumab. Among those who reported therapeutic response shortened, 15.9% (22 of 138) discontinued while the majority (116 of 138; 84.1%) continued ocrelizumab treatment. Of individuals reporting the adverse event of interest, those with relapsing-remitting MS more frequently remained on therapy (98 of 112; 87.5%) compared with those with primary progressive MS (18 of 26; 69.2%).\nConclusions: A wearing-off effect was infrequently reported and was not treatment limiting among people with MS in the real-world COMPASS patient support program. <\/jats:p>","DOI":"10.7224\/1537-2073.2024-083","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T13:58:47Z","timestamp":1751896727000},"page":"154","source":"Crossref","is-referenced-by-count":0,"title":["Wearing-Off Effect Reports in People With Multiple Sclerosis Receiving Ocrelizumab"],"prefix":"10.7224","author":[{"given":"Sarah A.","family":"Morrow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Gitman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofija","family":"Spasojevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Rassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Pasquarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kocho","family":"Fitovski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Vorobeychik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4242","published-online":{"date-parts":[[2025,6,2]]},"container-title":["International Journal of MS Care"],"original-title":[],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:12:16Z","timestamp":1752786736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/wearing-off-effect-ocrelizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":0,"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2024-083","relation":{},"ISSN":["1537-2073"],"issn-type":[{"type":"print","value":"1537-2073"}],"subject":[],"published":{"date-parts":[[2025,6,2]]}}}